Disease or Syndrome
Harbour BioMed Launches Élancé Therapeutics to Develop Next-Generation Obesity Treatments
Harbour BioMed, Élancé Therapeutics, Obesity therapies, Bispecific antibody technology, Next-generation treatments
Daiichi turns to Nosis for AI-designed RNA delivery tech
Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease
BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal
Burning Mouth Syndrome, Abecma, BMS, Abecma
Lila Sciences Emerges with $200M to Build AI-Powered Scientific Superintelligence Platform
AI, scientific discovery, autonomous labs, Flagship Pioneering, seed funding
Novo Nordisk’s CagriSema Weight Loss Drug Trial Results Disappoint Investors
CagriSema, weight loss, clinical trial, Novo Nordisk, stock price drop, obesity treatment
Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial
Sotyktu, deucravacitinib, psoriatic arthritis, Bristol Myers Squibb, POETYK PsA-2 trial, TYK2 inhibitor
Mineralys Phase 3 blood pressure pill data support potential FDA approval
United States Food and Drug Administration, Launch-HTN, Uncontrolled, Hypertensive disease, Approved
Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort
ARO-C3, IGA Glomerulonephritis, RNA Interference
AAD25: Ahead of CSU filing, Novartis’ BTK inhibitor shows sleep benefits
Chronic Spontaneous Urticaria, remibrutinib, Sleep, CSU, Novartis